Jasper Therapeutics, Inc. (NASDAQ:JSPR) Sees Significant Increase in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 1,940,000 shares, a growth of 10.2% from the October 31st total of 1,760,000 shares. Based on an average trading volume of 275,500 shares, the short-interest ratio is presently 7.0 days. Approximately 17.2% of the shares of the stock are sold short.

Jasper Therapeutics Stock Down 1.5 %

JSPR stock opened at $23.62 on Wednesday. The firm has a market cap of $354.30 million, a PE ratio of -4.98 and a beta of 2.18. The business has a 50 day moving average of $20.32 and a 200-day moving average of $20.92. Jasper Therapeutics has a 12-month low of $4.00 and a 12-month high of $31.01.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Braidwell LP bought a new stake in shares of Jasper Therapeutics during the 3rd quarter worth $9,091,000. Ally Bridge Group NY LLC raised its position in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares during the period. Samsara BioCapital LLC raised its holdings in Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock valued at $10,997,000 after acquiring an additional 59,642 shares during the period. FMR LLC purchased a new stake in Jasper Therapeutics during the 3rd quarter worth about $722,000. Finally, Bank of New York Mellon Corp bought a new position in Jasper Therapeutics in the 2nd quarter worth about $740,000. Institutional investors own 79.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on JSPR shares. HC Wainwright restated a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Thursday, October 24th. Royal Bank of Canada decreased their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. Evercore ISI reiterated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a report on Monday, August 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Finally, JMP Securities reiterated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics presently has a consensus rating of “Buy” and an average target price of $74.86.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.